Literature DB >> 28149895

RANKL inhibitors for osteosarcoma treatment: hope and caution.

Eva M Trinidad1, Eva González-Suárez1.   

Abstract

Entities:  

Year:  2016        PMID： 28149895      PMCID： PMC5233523          DOI： 10.21037/atm.2016.12.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  10 in total

1.  RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

Authors:  Guillermo Yoldi; Pasquale Pellegrini; Eva M Trinidad; Alex Cordero; Jorge Gomez-Miragaya; Jordi Serra-Musach; William C Dougall; Purificación Muñoz; Miguel-Angel Pujana; Lourdes Planelles; Eva González-Suárez
Journal:  Cancer Res       Date:  2016-08-01       Impact factor: 12.701

2.  RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Authors:  Eva Gonzalez-Suarez; Allison P Jacob; Jon Jones; Robert Miller; Martine P Roudier-Meyer; Ryan Erwert; Jan Pinkas; Dan Branstetter; William C Dougall
Journal:  Nature       Date:  2010-09-29       Impact factor: 49.962

Review 3.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

4.  RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

Authors:  Marta Palafox; Irene Ferrer; Pasquale Pellegrini; Sergi Vila; Sara Hernandez-Ortega; Ander Urruticoechea; Fina Climent; Maria Teresa Soler; Purificación Muñoz; Francesc Viñals; Mark Tometsko; Dan Branstetter; William C Dougall; Eva González-Suárez
Journal:  Cancer Res       Date:  2012-04-10       Impact factor: 12.701

5.  Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice.

Authors:  Sam D Molyneux; Marco A Di Grappa; Alexander G Beristain; Trevor D McKee; Daniel H Wai; Jana Paderova; Meenakshi Kashyap; Pingzhao Hu; Tamara Maiuri; Swami R Narala; Vuk Stambolic; Jeremy Squire; Josef Penninger; Otto Sanchez; Timothy J Triche; Geoffrey A Wood; Lawrence S Kirschner; Rama Khokha
Journal:  J Clin Invest       Date:  2010-08-09       Impact factor: 14.808

6.  Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine.

Authors:  Koji Akeda; Yuichi Kasai; Toshihiko Sakakibara; Akihiko Matsumine; Norihiko Takegami; Junichi Yamada; Akihiro Sudo
Journal:  Spine (Phila Pa 1976)       Date:  2015-05-15       Impact factor: 3.468

Review 7.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.

Authors:  Michael S Isakoff; Stefan S Bielack; Paul Meltzer; Richard Gorlick
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

8.  RANK expression as a prognostic and predictive marker in breast cancer.

Authors:  Berit Maria Pfitzner; Daniel Branstetter; Sibylle Loibl; Carsten Denkert; Bianca Lederer; Wolfgang Daniel Schmitt; Frank Dombrowski; Martin Werner; Thomas Rüdiger; William C Dougall; Gunter von Minckwitz
Journal:  Breast Cancer Res Treat       Date:  2014-04-16       Impact factor: 4.872

9.  RANK and RANK ligand expression in primary human osteosarcoma.

Authors:  Daniel Branstetter; Kathy Rohrbach; Li-Ya Huang; Rosalia Soriano; Mark Tometsko; Michelle Blake; Allison P Jacob; William C Dougall
Journal:  J Bone Oncol       Date:  2015-07-29       Impact factor: 4.072

Review 10.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561
  10 in total
  6 in total

Review 1.  The Osteoclast Traces the Route to Bone Tumors and Metastases.

Authors:  Sharon Russo; Federica Scotto di Carlo; Fernando Gianfrancesco
Journal:  Front Cell Dev Biol       Date:  2022-05-13

Review 2.  Emerging trends in immunotherapy for pediatric sarcomas.

Authors:  Kyle A Dyson; Brian D Stover; Adam Grippin; Hector R Mendez-Gomez; Joanne Lagmay; Duane A Mitchell; Elias J Sayour
Journal:  J Hematol Oncol       Date:  2019-07-16       Impact factor: 17.388

Review 3.  Emerging Anticancer Potentials of Selenium on Osteosarcoma.

Authors:  Kok-Lun Pang; Kok-Yong Chin
Journal:  Int J Mol Sci       Date:  2019-10-25       Impact factor: 5.923

Review 4.  Osteosarcoma mechanobiology and therapeutic targets.

Authors:  Zunaira Shoaib; Timothy M Fan; Joseph M K Irudayaraj
Journal:  Br J Pharmacol       Date:  2021-12-21       Impact factor: 9.473

Review 5.  Understanding and Modeling Metastasis Biology to Improve Therapeutic Strategies for Combating Osteosarcoma Progression.

Authors:  Timothy M Fan; Ryan D Roberts; Michael M Lizardo
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

6.  Evaluation of the Receptor Activator of Nuclear Factor Kappa B Ligand (RANKL) Expression in Osteosarcoma and Its Association with the Clinicopathological Data.

Authors:  Hui Heng Chua; Sharifah Emilia Tuan Sharif; Wan Faisham Nu'man Wan Ismail; Muhamad Syahrul Fitri Zawawi; Sarimah Abdullah
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.